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Abstract Adducins are cytoskeletal actin-binding proteins
(α, β, γ) that function as heterodimers and heterotetramers
and are encoded by distinct genes. Experimental and
clinical evidence implicates α- and β-adducin variants in
hypertension and renal dysfunction. Here, we have
addressed the role of α- and β-adducin on glomerular
function and disease using β-adducin null mice, congenic
substrains for α- and β-adducin from the Milan hyperten-
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DOI 10.1007/s00109-009-0549-xsive (MHS) and Milan normotensive (MNS) rats and
patients with IgA nephropathy. Targeted deletion of β-
adducin in mice reduced urinary protein excretion, preceded
by an increase of podocyte protein expression (phospho-
nephrin, synaptopodin, α-actinin, ZO-1, Fyn). The intro-
gression of polymorphic MHS β-adducin locus into MNS
(Add2, 529R) rats was associated with an early reduction of
podocyte protein expression (nephrin, synaptopodin, α-
actinin, ZO-1, podocin, Fyn), followed by severe glomer-
ular and interstitial lesions and increased urinary protein
excretion. These alterations were markedly attenuated when
the polymorphic MHS α-adducin locus was also present
(Add1, 316Y). In patients with IgA nephropathy, the rate of
decline of renal function over time was associated to
polymorphic β-adducin (ADD2, 1797T, rs4984) with a
significant interaction with α-adducin (ADD1, 460W,
rs4961). These findings suggest that adducin genetic
variants participate in the development of glomerular
lesions by modulating the expression of specific podocyte
proteins.
Keywords Adducin.Geneticrenaldisease.Glomerular
disease.IgAnephropathy.Podocytes.Proteinuria
Introduction
Renal failure, triggered by a variety of factors, is a major
and costly health care burden. After an apparently similar
initial glomerular injury, large individual variations occur in
the rate of progression toward renal failure as well as in the
magnitude of urinary protein excretion, which is the major
predictor of disease progression [1]. Polymorphisms within
genes encoding a few proteins associated with the podocyte
actin cytoskeleton are responsible for glomerular protein-
uria and progression toward failure in some monogenic and
polygenic glomerular diseases [2–5].
Adducin is a heterodimeric protein composed by α, β,
and γ subunits, encoded by distinct genes, that regulate
actin polymerization and bundling as well as basic cellular
functions involving the actin cytoskeleton, such as ion
transport, cell motility, morphology, and adhesion [6, 7].
Genetic variations within adducin genes have been shown
to be involved in primary hypertension in rats and humans
[8–11].
To date, no link has been suggested between adducin
polymorphisms and podocyte or glomerular function [2].
Indeed, α-a n dβ-adducin polymorphisms have been
variously found to be associated with progression of renal
failure in the presence of overt nephropathy or with decay
of renal function in population studies [12–16], although
the results have not been consistent [17]. Polymorphisms
within the α- and β-adducin genes occur in rodents (α-
adducin, Add1, F316Y; β-adducin, Add2, Q529R) [7, 8, 10]
and humans (α-adducin, ADD1, G460W, rs4961 and
S586C, rs4963; β-adducin, ADD2, C1797T, rs4984)[ 9,
10], although at different positions, therefore different
outcomes might be expected between species as function
of these genetic variants. These observations call for a set
of experimental and clinical approaches aimed at establish-
ing whether these genetic variations within the α- and β-
adducin genes are associated with changes in glomerular or
podocyte function both in rodents and humans. This aim
was pursued with the following three approaches to
evaluate the impact of adducin variations across different
contexts and to test to what extent rodent data may help in
understanding human data: (1) the effect of the knockout of
the β-adducin gene in mice on blood pressure, urinary
protein excretion, and podocyte protein expression; (2) the
effect of the introgression of a DNA segment, harboring the
polymorphic α-a n dβ-adducin loci from the Milan
hypertensive rat strain (MHS) into the normotensive strain
(MNS; congenic rat substrains) on blood pressure, urinary
protein excretion, glomerular morphology, and function and
podocyte protein expression; and (3) the association of α-
and β-adducin genotypes with the rate of decline of renal
function in patients with IgA nephropathy.
IgA nephropathy was selected as disease model for
several reasons, among which: (1) it is the commonest
glomerulonephritis worldwide, (2) its outcome is extremely
variable, spanning from decades of normal renal function to
fast progression toward end stage renal disease [18], and (3)
few clinical features have been detected as predictors of
progression rate [19].
Materials and methods
Animal models
All procedures for animal care were carried out in
accordance with Prassis Institutional Guidelines. The care
and husbandry of animals complied with the European
Directives no 86/609 and with the Italian Law (DL116,
January 27, 1992). The authorization for animal use in
Prassis Laboratories was obtained from the Italian Health
Authority. Animals had free access to the chow (standard
diet, Altromin, Rieper, Italy) and to tap water and were
maintained under controlled conditions of air temperature
(22±2°C), relative humidity (50±15%), and day/night
cycle (12 h):
1. β-Adducin (Add2) null mouse model: β-adducin
knockout mice (official strain designation 129-
Add2
tm1Llp/Llp) have been previously described [20].
Wild-type 129/Sv mice, carrying the same β-adducin
204 J Mol Med (2010) 88:203–217polymorphism (Q529R) described in the MHS rats [7],
were used as controls.
2. Selection of congenic rat substrains from MHS and
MNS parental strains: MHS, hypertensive, and MNS,
normotensive, parental rats were derived from the
internal stock colony (Prassis sigma-tau). Congenic rat
strains were obtained from MHS hypertensive and
MNS normotensive strains, as described [21]. The
donor strain was the MHS and the receiving genetic
background was the MNS. The integrated physical and
linkage map of the congenic segment indicated that the
reciprocal congenics for α-adducin (Add1) contained a
minimum/maximum of 1.0/8.8 Mb (6.6 cM) and that
for β-adducin (Add2) a minimum/maximum of 1.0/
26.4 Mb (13.5 cM) [21].
Systolic blood pressure (SBP) and heart rate were
recorded in conscious rats (from 2 to 6 months of age)
and in mice (at 8 and 11 months) by an indirect tail-cuff
plethysmographic method (BP recorder, U. Basile, Varese,
Italy).
Biochemical assays for urinary parameter measurements
Urinary parameters were measured in conscious male rats at
1.5, 3, 6, 8, and 11 months of age. Rats were housed in
individual metabolic cages and had free access to water and
food. Urinary parameters were also measured in conscious
wild-type and knockout mice at 8 and 11 months of age.
Mice received a bolus of 1 ml physiological solution by
gavages, and urine was collected over a period of 6 h. Urine
samples were analyzed for the following parameters:
volume, pH, osmolality, Na
+ and K
+ concentrations (IL
943 photometer), total protein excretion (total protein Kit,
Sentinel Diagnostics, Milan, Italy), and creatinine (colori-
metric Kit, Sentinel Diagnostics).
Histological and immunohistochemical studies
Renal tissue samples for light microscopy were fixed in 4%
buffered paraformaldehyde and embedded in paraffin.
Routine staining was performed on 2-μm-thick sections
according to standard techniques [22].
For immunofluorescence and immunohistochemistry,
unfixed renal tissue was embedded in OCT compound
(Miles Scientific, Naperville, IL, USA), snap-frozen in a
mixture of isopentane and dry-ice, and stored at −80°C.
Five-micrometer sections were placed on slides and fixed in
cold acetone. In indirect immunofluorescence, the bound
primary antibodywas detected by Alexa Fluor 488 antirabbit
or antimouse IgG (Invitrogen). For immunohistochemistry,
after blocking endogenous biotin and endogenous peroxi-
dase, the primary antibody was followed by an appropriate
biotinylated secondary antibody and peroxidase-labeled
streptavidin (both from Invitrogen), finally developed by
diaminobenzidine (Sigma). Slides were mounted either with
Vecta-shield aqueous mounting medium (Vector Laborato-
ries, DBA Italia SRL) or with Bio Mount (Bio Optica, Milan,
Italy).
Glomeruli and podocyte isolation
Kidneys were taken from 7- to 10-day-old rats. Glomeruli
were isolated by sieving then seeded in culture flasks
precoated with collagen type IV (Sigma-Aldrich) at 37°C in
5% CO2 atmosphere. On days 4 to 5, podocyte growth
started, and by day 8, glomeruli were detached using
trypsin–EDTA and filtered through the 36-μm mesh to
eliminate glomeruli. Second passage podocytes, >90% pure
as judged by light microscopy, were seeded on flasks and
chamber slides. Cell characterization was performed by
immunofluorescence, using markers for podocytes (neph-
rin, podocin), epithelial (cytokeratin), smooth muscle (α-
SMA), and endothelial cells (CD31).
Western blotting
Samples were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, blotted and overnight
incubated at 4°C with specific primary antibodies, followed
by 1 h incubation with fluorescent secondary antibodies
(Alexa Fluor), then analyzed and quantified by Odyssey
Infrared Imaging Detection System (LI-COR Biosciences).
Antibodies were anti-α- and anti-β-adducin (raised by S.
Salardi in Prassis); anti-nephrin, anti-Fyn (Santa Cruz);
anti-phospho-nephrin (kindly provided by Larry Holz-
man); anti-vimentin, anti-ZO-1, anti-α-SMA (Invitrogen);
anti-synaptopodin (Progen Biotechnik); anti-α-actinin
(Calbiochem); anti-podocin, anti-actin (Sigma-Aldrich);
and anti-cytokeratin, anti-CD31 (Abcam).
Human studies
Informed consent was obtained from all participants in the
study, which was approved by the Ethical Committee of the
San Raffaele Hospital, Milan, Italy.
Three hundred seventy-three patients, with biopsy
proven primary IgA nephropathy (IgAN), were included
in the study. Enrolling patients began in 1994 with the
intent to recruit both incident cases and cases that were
already being followed up. Only Caucasian patients of
Italian origin were selected. The only selection criteria were
willingness of the patient to participate and a follow-up
longer or equal to 4 years. Clinical and anthropometric
parameters, blood pressure values, and laboratory data at
the time of renal biopsy were collected. After renal biopsy,
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analyses and clinical evaluations (at least once per year) at
their respective centers. Urinary protein excretion varies
considerably from day to day, but average values remain
fairly constant in IgAN, at least within the first 3 years after
diagnosis [23]; the average of the urinary protein excretion
over the first 2 years after biopsy was therefore used for
analysis. Glomerular filtration rate (GFR) was computed
with the Cockcroft–Gault formula [24]. The individual rate
of renal function decline was computed separately for each
patientwiththe leastsquaresmethodandexpressedthelossof
GFR per year (ml min
−1 year
−1). Twenty-eight subjects were
excluded because their data set was incomplete or their DNA
failed to amplify and 17 because they showed a biphasic
course of their GFR over time. Their renal function remained
almost normal (serum creatinine less than 1.5 mg/dl) and
stable for a variable number of years, before dropping
abruptly with fast progression to end stage renal disease. We
and others [25] considered these cases as atypical.
The minimum number of GFR determinations used to
compute progression rate was four per patient, while the
average number of GFR values analyzed was 9.28±0.28
(8.74–9.83, 95% confidence interval) per patient. Severity of
renal damage according to Lee et al. [26] was scored by two
experienced pathologists, blind for patient's clinical features,
outcome, and adducin genotype, with an interrater reproduc-
ibility higher than 90%. The grading system of Lee et al.
consists of a single score (grades I to V) and summarizes
glomerular and, to a lesser degree, interstitial lesions. Higher
grades include crescent formation and interstitial fibrosis.
Genotyping for α- and β-adducin
Genotyping was carried out on an ABI PRISM 7700
Sequence Detection System using the 5′ nuclease detection
assay, as described [27].
Statistical analysis
Statistical analysis was performed with SPSS 16.0 (SPSS
Inc., Chicago, IL, USA) and STATA 8 (Stata Corporation,
College Station, TX, USA). Quantitative data were ana-
lyzed with Student's t test, one-way analysis of variance
(ANOVA), or by simple or multiple linear regression when
appropriate. A p value <0.05 (two-tailed) was considered
significant. For human studies, progression rate was defined
as the GFR decay each year (ml min
−1 year
−1) in each
individual subject. First simple linear regression models
were tested with renal function loss as the dependent
variable and, separately one for each model, urinary protein
excretion, serum creatinine, serum IgA, body mass index
(BMI),andhypertensionatdiagnosis,gender,ageofonset,and
severity grading of Lee et al. as independent variables. Then,
the same variables were all entered in a multiple regression
model in a stepwise procedure.
Test of genetic effects and interaction was performed
with two-locus model fitting, and hypothesis testing was
conducted via least squares regression analysis [28]. The fit
of the different genetic models (additive versus dominant)
was compared and evaluated based on the respective F
values of each model, and the one yielding the greatest F
test was assumed to be the most appropriate. The effects of
the various nongenetic factors considered above (urinary
protein excretion, serum creatinine, serum IgA, BMI,
hypertension at diagnosis, gender, age of onset, severity
grading of Lee et al.) were tested using multivariate
analysis, by including them as main effects as well as
interaction with genotypes. The nonsignificant effects (all
of the above, except urinary protein excretion) were
discarded from the model in a stepwise procedure.
As most of the patients were recruited before generalized
use of angiotensin-converting enzyme (ACE) inhibition,
only about 47% of the subjects received an antihypertensive
therapy, either ACE inhibitors (ACEI; 37%) or other drugs.
This may affect the level of proteinuria. For this reason and
for the fact that ACE inhibitor treatment was evenly
distributed according to ADD1 (c2
1 ¼ 0:53; p=0.46) and
ADD2 (c2
1 ¼ 0:80; p=0.37) genotype, ACE inhibition was
not accounted for in the multivariate analysis but analyzed
separately.
The authors had full access to the data and take
responsibility for its integrity. All authors have read and
agreed to the manuscript as written.
Results
Localization of α- and β-adducin in the kidney
Immunostainings performed with specific anti-adducin
antibodies in mice, rats, and humans revealed the presence
of α- and β-adducin in renal glomeruli. Figure 1 shows a
typical immunofluorescence analysis of rat glomeruli.
Immunogold electron microscopy (supplementary data,
Fig. S1) in rat kidneys indicated that both proteins were
ubiquitously present in glomerular cells. In particular, α-
and β-adducins were present in podocytes. Reverse
transcriptase polymerase chain reaction, immunogold, and
Western blot analysis carried out in mouse, rat, and human
podocytes confirmed the presence of mRNA and protein for
α- and β-adducin isoforms (not shown).
β-Adducin null mice
Systolic blood pressure SBP did not differ between male
and female β-adducin knockout mice and age- and sex-
206 J Mol Med (2010) 88:203–217matched wild-type mice at 8 and 11 months of age. Figure 2
shows SBP in 11-month-old mice.
Renal studies No difference in urinary volume or Na
+,K
+,
and creatinine excretion was detected between male and
female knockout mice and wild-type controls at 8 and
11 months of age (not shown). However, compared to
controls, male and female knockout mice showed a
significant reduction of urinary protein excretion normal-
ized for urinary creatinine excretion at both ages. Figure 2
shows proteinuria/creatinine ratio in 11-month-old mice.
Immunostaining of proteins belonging to podocyte slit
diaphragm (such as nephrin and Fyn) and foot process
cytoskeleton (such as synaptopodin, α-actinin, and ZO-1),
performed in kidney sections from male 1.5-month-old
wild-type and knockout mice, showed no β-adducin in
knockout mice, a similar staining for α-adducin and nephrin
but an increased staining for synaptopodin, α-actinin, ZO-1,
and Fyn in knockout mice (Fig. 3;s u p p l e m e n t a r yF i g .S 2).
AWestern blot analysis, performed on isolated glomeruli
of 1.5-month-old mice, showed no β-adducin in knockout
mice and a similar content of α-adducin between the two
groups (Fig. 4). Total nephrin was not different while
phosphorylated nephrin was significantly increased in
knockout mice, together with synaptopodin, α-actinin,
ZO-1, and Fyn. Podocin and actin were similar between
the two groups (Fig. 4). The normalization of protein
contents against actin did not change the pattern of
differences between the two groups of mice. The supple-
mentary Fig. S3 shows the Western blots of the individual
Fig. 1 Immunofluorescence
analysis for α- and β-adducin
localization in renal tissues.
Immunostaining was performed
on mouse, rat, and human renal
sections by using specific anti-
adducin antibodies and indicated
the presence of α- and β-
adducin in glomerular cells. The
figure shows a typical indirect
immunofluorescence (×400
magnification) of rat glomeruli
Fig. 2 Effect of β-adducin
knockout on systolic blood
pressure and proteinuria/creati-
nine ratio in mice. Indirect sys-
tolic blood pressure (upper) and
urinary protein excretion nor-
malized for urinary creatinine
(lower) were measured in male
and female wild-type (WT) and
knockout (KO) mice at 8 and
11 months of age. Similar
results have been obtained at the
two ages. The figure shows the
results at 11 months. Data are
mean ± SEM. Mouse numbers
are indicated in the bars.* * p<
0.01 KO vs. WT
J Mol Med (2010) 88:203–217 207renal glomerular preparation from wild-type (n=5) and β-
adducin knockout mice (n=5), probed with the specific
antibodies. These data suggest that the reduced proteinuria
observed in β-adducin knockout mice, as compared to
wild-type controls, is preceded by an increased expression
of specific podocyte marker proteins.
Congenic rat substrains for α- and β-adducin
Systolic blood pressure As published [21], the introgression
of α-adducin from MHS into the MNS genetic background
(NA congenic), but not that of β-adducin (NB congenic),
significantly raises SBP in NA over MNS. Here, we have
additionally demonstrated that in double-congenic strains
(NAB), where polymorphic α-a n dβ-adducin genes were
simultaneously transferred from MHS into MNS rats, SBP
did not differ from that of MNS at any age. Figure 5 shows
SBP at 3 months. These data suggest that, although β-
adducin, per se, seems not to affect SBP, it blunts the
hypertensive effect of α-adducin.
Renal studies MNS rats develop an age-dependent glomer-
ulosclerosis and proteinuria [29–31] sustained by an in-
creased glomerular production of thromboxane [31], while
MHS are protected from a glomerular damage. To assess the
involvement of α-a n dβ-adducin gene polymorphisms on
the progression of renal alterations, urinary parameters were
measured in rat strains at different ages (1.5, 3, 6, 8,
11 months). No urinary parameter (including 24 h urinary
Na
+,K
+, creatinine, and proteinuria) differed among the
various strains at 1.5 and 3 months of age (not shown).
Protein excretion greatly increased with age in MNS and
even more severely in NB, while it remained low over time
in MHS, NA, and NAB. Figure 5 shows proteinuria
normalized for urinary creatinine excretion at 6 months of
age. The values of proteinuria in rats are higher than in mice
because of the presence of glomerulosclerosis in MNS rats
[29–31].
Histological studies, carried out in kidney preparations
of rat strains at 3 months of age, showed normal glomeruli
and normal interstitium (not shown), whereas at 6 and
Fig. 4 Western blot analysis of podocyte proteins in isolated
glomeruli from β-adducin knockout mice. Renal glomeruli were
isolated from 1.5-month-old male wild-type and β-adducin knockout
mice. Five mice for each group were analyzed by Western blotting
(10 µg protein/lane) using specific antibodies as indicated. The
densitometric analysis is reported. The optical densities are expressed
as arbitrary units. Data are mean ± SEM. *p<0.05 KO vs. WT. Figure
S3 in supplementary data shows the Western blots of the individual
renal glomerular preparations from wild-type and β-adducin knockout
mice
Fig. 3 Immunofluorescence analysis of podocyte proteins and α- and
β-adducin in mouse kidney sections. Immunohistochemical expres-
sion of podocyte proteins from slit diaphragm (nephrin, Fyn) and foot
process cytoskeleton (synaptopodin, α-actinin, ZO-1) and α- and β-
adducin was evaluated in kidney preparations from 1.5-month-old
male wild-type and β-adducin knockout mice. Five mice for each group
were investigated. Magnification: nephrin ×1,000; synaptopodin ×630;
α-actinin WT ×630; α-actinin KO ×400; ZO-1 ×400; Fyn ×1,000; α-
and β-adducin ×400. Figure S2 in supplementary data shows the
quantitative immunofluorescence analysis
208 J Mol Med (2010) 88:203–217Fig. 5 Systolic blood pressure and proteinuria/creatinine ratio in
congenic rat substrains for α- and β-adducin. Indirect systolic blood
pressure (left) and urinary protein excretion normalized for creatinine
excretion (right) were measured in male parental hypertensive MHS
and normotensive MNS rats and in congenic substrains obtained by
introgressing α-adducin (NA), β-adducin (NB), and αβ-adducin
(NAB) from MHS into the MNS genetic background. The measure-
ments have been done in rats at 3 (left) and 6 (right) months of age.
Data are mean ± SEM. Rat numbers are indicated in the bars.N o
variation of heart rate was observed in any congenic substrain as
compared to MNS (not shown). *p<0.05, **p<0.01, ***p<0.001 vs.
MNS; $$p<0.01 vs. NB
Fig. 6 Glomerular morphologic analysis in kidneys from congenic rat
substrains for α- and β-adducin. Histomorphological studies have
been conducted in kidney preparations from male parental hyperten-
sive MHS and normotensive MNS rats and in congenic substrains for
α-adducin (NA), β-adducin (NB), and αβ-adducin (NAB). The
analysis has been performed in rats at 6 months of age. The increased
urinary protein excretion of MNS, which was even higher in NB,
paralleled the appearance of glomerular and interstitial alterations as
described in the text. The presence of MHS α-adducin in MHS, NA,
and NAB appeared to protect against proteinuria and glomerular
damage. Five rats for each group were analyzed. Magnification: MHS
and NAB ×400; MNS, NA, and NB ×250. Figure S4 in supplementary
data shows the quantitative morphometric analysis
J Mol Med (2010) 88:203–217 20911 months of age, glomerular and interstitial damage
paralleled the increase of proteinuria in MNS as compared
to MHS (Fig. 6). In NB, where a massive proteinuria was
observed (Fig. 5), histological alterations (mesangial pro-
liferation, mesangial matrix expansion, segmental glomer-
ulosclerosis, interstitial leukocyte infiltration, focal areas of
interstitial fibrosis, tubular dilation and giant tubular protein
casts), were even more severe than in MNS rats (Fig. 6).
Conversely, no histological alteration was observed in
MHS, NA, and NAB strains, where MHS α-adducin was
present (Fig. 6). The supplementary Fig. S4 shows the
quantitative morphometric analysis of histological data
obtained from five rats per group. Electron microscopy,
carried out in 3-month-old rats, confirmed the presence of
podocyte foot process effacement in MNS and NB, while
NA appeared protected (supplementary Fig. S5).
The immunohistochemical expression of podocyte pro-
teins, evaluated in kidney preparations from 1.5-month-old
rats, where no difference in proteinuria was present among
all strains, showed a decreased expression of nephrin,
synaptopodin, α-actinin (Fig. 7), ZO-1, Fyn (Fig. 8), P-
cadherin (not shown), and α-adducin (Fig. 9) in MNS and
NB strains as compared to MHS, NA, and NAB.
Conversely, β-adducin (Fig. 9) and vimentin (Fig. 8), a
microfilament localized in the podocyte cell body, were
normally expressed in all strains. The supplementary Figs.
S6 and S7 show the quantitative analysis of these data
obtained from five rats per group. Note that α-adducin,
but not β-adducin, was less expressed in MNS and NB
(Fig. S7).
AWestern blot analysis of isolated glomeruli from 25- to
45-day-old rats showed a similar content of actin but a
reduced expression of nephrin, either normalized or not
against actin, in MNS and NB as compared to MHS, NA,
and NAB rats (Fig. 10). The supplementary Fig. S8 shows
the Western blots for nephrin and actin of the individual
renal glomerular preparations from rat substrains. Five rats
per group were analyzed.
Furthermore, a Western blot analysis of some podocyte
markers, performed on primary cultures of glomerular
podocytes from 10-day-old rats, confirmed a decreased
expression of nephrin, α-actinin, ZO-1, podocin, and α-
adducin in MNS and NB compared to NA podocytes
(Fig. 11). Conversely, β-adducin (supplementary Fig. S9)
and actin expression (Fig. 11) was similar among the three
groups. The normalization of protein contents against actin
Fig. 7 Immunofluorescence analysis of podocyte proteins in kidney
sections from congenic rat substrains for α-a n dβ-adducin.
Immunohistochemical expression of podocyte proteins (nephrin,
synaptopodin, α-actinin) was evaluated in kidney preparations from
1.5-month-old male MHS, MNS rats and in congenic substrains for α-
adducin (NA), β-adducin (NB), and αβ-adducin (NAB). Five rats for
each group were analyzed. Magnification: nephrin MHS and NA ×250;
nephrin MNS, NB, and NAB ×400; synaptopodin and α-actinin ×400.
Figure S6 in supplementary data shows the quantitative immunofluo-
rescence analysis
210 J Mol Med (2010) 88:203–217did not change the pattern of differences among the three
groups of rats. The supplementary Fig. S9 shows the
Western blots of the individual glomerular podocyte
preparations from congenic rats.
The present findings suggest that the pronounced
proteinuria in MNS and NB strains, carrying the β-
adducin genetic variant, is preceded by an early alteration
of podocyte protein expression responsible for the changes
Fig. 9 Immunofluorescence analysis of α- and β-adducin in kidney
sections from congenic rat substrains. Immunohistochemical expres-
sion of α- and β-adducin was evaluated in kidney preparations from
1.5-month-old male MHS, MNS rats and in congenic substrains for α-
adducin (NA), β-adducin (NB), and αβ-adducin (NAB). Five rats for
each group were analyzed (×400 magnification). Figure S7 in
supplementary data shows the quantitative immunofluorescence
analysis
Fig. 8 Immunofluorescence analysis of podocyte proteins in kidney
sections from congenic rat substrains for α- and β-adducin. Immuno-
histochemical expression of podocyte proteins (ZO-1, Fyn, vimentin)
was evaluated in kidney preparations from 1.5-month-old male MHS,
MNS rats and in congenic substrains for α-adducin (NA), β-adducin
(NB), and αβ-adducin (NAB). Five rats for each group were analyzed.
Magnification: ZO-1, Fyn, vimentin ×400. Figure S6 in supplemen-
tary data shows the quantitative immunofluorescence analysis
J Mol Med (2010) 88:203–217 211of the glomerular filtration barrier permeability associated
with protein leakage. Conversely, the MHS α-adducin
variant seems to be protective in MHS, NA, and NAB
rats.
Renal function loss in patients with IgA nephropathy
Baseline data of the total sample are reported in Table 1.A t
univariate analysis, urinary protein excretion (R
2=0.214,
Fig. 10 Western blot analysis of nephrin and actin in isolated
glomeruli from congenic rat substrains for α- and β-adducin. Renal
glomeruli were isolated from 25–45-day-old male MHS, MNS rats
and congenic substrains for α-adducin (NA), β-adducin (NB), and αβ-
adducin (NAB). Five rats for each group were analyzed by Western
blotting (10 µg protein/lane) using specific antibodies against nephrin
and actin. The densitometric analysis is reported as arbitrary units.
Data are mean ± SEM. *p<0.05, **p<0.01 vs. MNS. Figure S8 in
supplementary data shows the Western blots for nephrin and actin of
the individual renal glomerular preparations from rat substrains
Fig. 11 Glomerular podocyte cultures from MNS rats and congenic
substrains for α-adducin (NA) and β-adducin (NB). Neonatal rats
(<10 days old) were used for podocyte culture preparations that were
analyzed by Western blotting (10 µg protein/lane) using specific
antibodies as indicated. Four preparations from MNS and NA and
seven from NB rats were analyzed. The densitometric analysis is
reported. The optical densities are expressed as arbitrary units. Data
are mean ± SEM. *p<0.05 vs. MNS. Figure S9 in supplementary data
shows the Western blots of the individual glomerular podocyte
preparations from rat substrains
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2=0.103, p<0.001), serum creat-
inine (R
2=0.036, p=0.001) at diagnosis and score of Lee et
al. (R
2=0.066, p<0.001) correlated significantly with renal
function loss, while age of onset, serum IgA concentration,
gender, and BMI did not. When all were included in a
multiple regression model, only urinary protein excretion and
hypertension at diagnosis gave an independent significant
contribution to the model. The overall variance increased
very little from that explained by proteinuria alone (R
2 from
0.214 to 0.237), with only minimal contribution from
hypertension at diagnosis (R
2=0.023, p=0.002).
The frequencies of ADD1 (α-adducin) and ADD2 (β-
adducin) genotypes are summarized in Table 2. Clinical
characteristics according to ADD1 and ADD2 genotype are
reported in Tables 3 and 4, respectively. Carriers of at least
one ADD2 1797T allele had slightly higher blood pressure.
The degree of renal function loss was affected by ADD2
(Table 4), but not by ADD1 genotypes (Table 3).
The ANOVA table for the model, considering ADD1
460Trp allele and ADD2 1797T allele dominant, is shown
in Table 5. The R
2 for the model, including the effect of
urinary protein excretion at diagnosis, was 0.245. When
only ADD1 and ADD2 genotypes and their interaction
were included, the model remained statistically significant,
though the variance explained was substantially lower (R
2=
0.057, p=0.0004). Note that also ADD1–ADD2 interaction
was statistically significant (p=0.0174).
Neither ADD1 nor ADD2 was associated to proteinuria.
However, only in carriers of the adducin mutant alleles, ACE
inhibitors significantly decreased the level of proteinuria
(ADD1 460Trp 1.87±0.24 versus 1.18±0.17 g/24 h, p=0.02;
ADD2 1797T 1.96±0.2 versus 1.14±0.17 g/24 h, p=0.04).
Conversely, in carriers of the adducin wild-type alleles, ACE
inhibitors did not affect proteinuria (ADD1 Gly460Gly
1.63±0.12 versus 1.38±0.11 g/24 h, p=0.15; ADD2
C1797C 1.56±0.13 versus 1.28±0.11 g/24 h, p=0.13).
To provide more information on the relationships
between GFR loss per year, genotypes, and level of
proteinuria at onset, these variables were analyzed with an
additional linear model inwhich the degree ofproteinuria was
analyzed as tertiles, and least square means were obtained for
the rate of renal function loss in each of these classes. The rate
of renal function decline was more than double in carriers of
the ADD1 460Trp + ADD2 1797Tcombination of genotypes
(−4.04±1.15 ml min
−1year
−1 per gram of urinary protein)
than in carriers of the ADD1 Gly460Gly + ADD2 C1797C
one (−1.64±0.36 ml min
−1year
−1; p=0.005), with interme-
diate and similar values for the combinations where only one
mutant adducin (either ADD1 or ADD2) genotype was
present (Gly460Gly+1797T −3.04±0.57 ml min
−1year
−1;
460Trp+C1797C −3.09±0.44 ml min
−1year
−1).
Glomerular immunohistochemical analysis for α- and
β-adducin in IgA nephropathy Twenty IgAN patients,
chosen for the availability of the material for immunohisto-
chemistry, have been analyzed and divided into two groups
according to the rate of renal function decline: stable renal
function (nonprogressors) or rapidly progressing toward end-
stagerenalfailure(progressors).Wedidnotfindanydifference
in α-a n dβ-adducin staining. Theresults oftwo representative
patients are shown in the supplementary Fig. S10.
Discussion
The major findings described in the present work are (1) the
localization of α-a n dβ-adducin in glomerular podocytes
in mice, rats, and humans; (2) in β-adducin null mice,
Table 1 Baseline patient demographics, clinical and laboratory data
Variable Mean (range) ± SEM
Age at presentation (years) 31.51 (16–77)±0.77
Age at biopsy (years) 34.73 (16–77)±0.79
Males (% men) 247 (75.3%)
Hypertensive (%) 158 (48.2%)
Antihypertensive treatment (%) 152 (46.3%)
Macrohematuria (%) 143 (43.6%)
Body weight (kg) 70.21±0.84
Height (cm) 169.25±2.05
Body mass index (kg/m
2) 24.36±0.22
Serum creatinine (mg/dl) 1.51±0.07
Creatinine clearance (ml/min)
a 80.40±2.0
SBP (mmHg) 136.39±1.05
DBP (mmHg) 87.55±0.67
Urinary protein excretion (g/24 h) 1.46±0.07
Follow-up from presentation (years) 11.36 (4–23)±0.38
Follow-up from biopsy (years) 8.44 (4–19)±0.37
Renal function loss (ml/min year) −5.46±0.42
If not otherwise indicated, reported data are the ones collected at the
time of renal biopsy. Presentation means the first recorded/reported
episode of macrohematuria or microhematuria/proteinuria at urinalysis
aComputed with Cockcroft–Gault formula [24]
Table 2 Distribution of ADD1 (α-adducin) and ADD2 (β-adducin)
genotypes
ADD1 ADD2
Gly460Gly 231 (70.4%) C1797C 217 (66.2%)
Gly460Trp 85 (25.9%) C1797T 95 (29.0%)
Trp460Trp 12 (3.7%) T1797T 16 (4.9%)
Genotype frequencies are in Hardy–Weinberg equilibrium (test for
deviation from Hardy–Weinberg: p=0.826 for ADD1 and p=0.841 for
ADD2)
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morphic β-adducin variant (Q529R) as MHS rats, the
expression of proteins of podocyte slit membrane or foot
process cytoskeleton (such as phospho-nephrin, synaptopo-
din, α-actinin, ZO-1, Fyn) is increased, while the urinary
protein excretion was decreased. Therefore, the absence of
β-adducin reduced the glomerular permeability to proteins.
In contrast to erythrocytes [20], β-adducin deletion did not
induce a loss of α-adducin in glomeruli. (3) In congenic
rats, the decreased expression of key podocyte proteins
(such as nephrin, synaptopodin, α-actinin, ZO-1, podocin,
Fyn), followed by an increase of urinary protein excretion
and glomerular damage, traveled together with the DNA
segment containing the β-adducin polymorphism of MHS
rats. This effect was blunted by the simultaneous presence
of MHS α-adducin. The epistatic interaction between α-
and β-adducin suggests that the glomerular changes
observed here were very likely due to the adducin
Variable Gly460Gly (231) 460Trp (97) p
Mean (range) ± SEM Mean (range) ± SEM
Age at presentation (years) 31.5 (16–77)±0.91 31.6 (15–72)±1.42 n.s.
Age at biopsy (years) 34.8 (16–77)±0.95 34.6 (17–72)±1.43 n.s.
Males (% men) 175 (76%) 72 (74%) n.s.
Hypertensive (%) 144 (62%) 44 (45%) n.s.
Antihypertensive treatment (%) 108 (47%) 44 (45%) n.s.
Macrohematuria (%) 94 (41%) 49 (50%) n.s.
Body weight (kg) 70.3±0.71 70.1±1.02 n.s.
Height (cm) 169.4±0.56 168.8±0.76 n.s.
Body mass index (kg/m
2) 24.3±0.20 24.5±0.32 n.s.
Serum creatinine (mg/dl) 1.52±0.10 1.47±0.08 n.s.
Creatinine clearance (ml/min)
a 81.0±2.24 79.0±3.90 n.s.
SBP (mmHg) 135.8±1.20 137.7±1.90 n.s.
DBP (mmHg) 87.2±0.80 88.5±1.22 n.s.
Urinary protein excretion (g/24 h) 1.47±0.08 1.46±0.15 n.s.
Follow-up from presentation (years) 11.3 (4–23)±0.35 11.4 (4–23)±0.55 n.s.
Follow-up from biopsy (years) 8.3 (4–19)±0.30 8.7 (4–19)±0.49 n.s.
Renal function loss (ml/min year) −5.04±0.42 −6.46±1.00 n.s.
Table 3 Baseline patient demo-
graphics, clinical and laboratory
data according to ADD1 (α-
adducin) genotype
If not otherwise indicated,
reported data are the ones col-
lected at the time of renal biop-
sy. Presentation means the first
recorded/reported episode of
macrohematuria or microhema-
turia/proteinuria at urinalysis
a Computed with Cockcroft–
Gault formula [24]
Variable C1797C (217) 1797T (111) p
Mean (range) ± SEM Mean (range) ± SEM
Age at presentation (years) 31.5 (16–77)±0.95 31.6 (16–72)±1.31 n.s.
Age at biopsy (years) 34.9 (16–77)±0.99 34.4 (16–72)±1.33 n.s.
Males (% men) 168 (77%) 79 (71%) n.s.
Hypertensive (%) 99 (46%) 59 (53%) n.s.
Antihypertensive treatment (%) 94 (43%) 58 (52%) n.s.
Macrohematuria (%) 102 (47%) 41 (37%) n.s.
Body weight (kg) 70.9±0.72 68.9±1.00 n.s.
Height (cm) 169.4±0.53 168.8±0.80 n.s.
Body mass index (kg/m
2) 24.5±0.22 23.9±0.27 n.s.
Serum creatinine (mg/dl) 1.48±0.07 1.56±0.16 n.s.
Creatinine clearance (ml/min)
a 82.2±2.51 76.9±3.02 n.s.
SBP (mmHg) 134.8±1.12 139.5±2.01 0.041
DBP (mmHg) 86.6±0.78 89.3±1.22 0.054
Urinary protein excretion (g/24 h) 1.38±0.09 1.63±0.13 n.s.
Follow-up from presentation (years) 11.4 (4–23)±0.34 11.3 (4–21)±0.58 n.s.
Follow-up from biopsy (years) 8.4 (4–19)±0.24 8.6 (4–19)±0.49 n.s.
Renal function loss (ml/min year) −4.77±0.41 −6.82±0.92 0.043
Table 4 Baseline patient demo-
graphics, clinical and laboratory
data according to ADD2 (β-
adducin) genotype
If not otherwise indicated,
reported data are the ones col-
lected at the time of renal biop-
sy. Presentation means the first
recorded/reported episode of
macrohematuria or microhema-
turia/proteinuria at urinalysis
a Computed with Cockcroft–
Gault formula [24]
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decline increased when a specific combination of α- and β-
adducin polymorphisms was present. Taken together, these
observations strongly support the notion that αβ-adducin
heterodimers are involved in the molecular mechanisms
underlying the process of glomerular permeability, associ-
ated with an increase of protein excretion and progression
rate of glomerular failure.
In human IgAN, β-adducin polymorphism was associ-
ated to renal function decline, but not to the average urinary
protein excretion, at least during the first 2 years after
diagnosis. It is not clear whether this discrepancy with the
rodent findings is real or due to the complexity of the
human condition. In fact, in the human study, 47% of
patients were on ACEI or other antihypertensive treatment.
Renin–angiotensin system inhibition may differently affect
proteinuria and progression toward renal failure [32] and
may also differ across genotypes. In fact, the reduction of
proteinuria associated to ACEI treatment was significant
only in carriers of mutant ADD1 460Trp or ADD2 1797T
alleles. It is worth mentioning that the cell surface
expression of ACE is greater in human cultured fibroblasts
carrying the ADD1 Trp allele, or in renal cells transfected
with the ADD1 Trp allele, than in fibroblasts carrying the
ADD1 Gly allele, or renal cells transfected with the ADD1
Gly allele [33]. These observations, taken together with the
larger genetic heterogeneity of humans as compared to that
of inbred strains of rodents and the difference in the
adducin mutation sites, may account for the discrepancy
between humans and rodents on the genotype–proteinuria
relationship.
Nephrin is an essential component of the glomerular
podocyte junction [34] and participates to the formation of
the glomerular filtration barrier via interactions with
associated proteins, including the Src family protein kinase
Fyn [34–36]. Engagement of the nephrin ectodomain
induces Fyn activation that favors nephrin phosphorylation
[35] and the recruitment of adaptor proteins, such as Nck,
involved in the regulation of podocyte junction formation
and actin cytoskeletal dynamics [36]. Mutations of several
podocyte proteins, or the knockout of Fyn or nephrin in
mice, induce a rearrangement of the actin cytoskeleton and
the disruption of the filtration barrier leading to renal
disease [3, 4, 36].
Recently, also β-adducin has been shown to be a
specific target of Fyn [37]. Fyn binds and phosphorylates
β-adducin at Tyr
489, permitting its association with Fyn-
SH2 domain and translocation to the plasma membrane
[37]. Interestingly, the polymorphism (Q529R) identified in
the rat β-adducin C-terminal domain maps close to the Fyn-
dependent phosphorylation residue (Tyr
489).
The data presented here in β-adducin null mice and
congenic rats support the hypothesis that β-adducin may
induce a reduction of Fyn protein expression on the cell
membrane resulting in a downregulation of phosphorylated
nephrin and related podocyte proteins, such as synaptopo-
din, ZO-1, and α-actinin, associated with the appearance of
glomerular podocyte damage and proteinuria. Conversely,
the knockout of the β-adducin gene in mice, or the
presence of the polymorphic α-adducin variant in MHS,
NA, or NAB rat substrains, seems to be protective. This
effect appears to occur through the reactivation of the
nephrin signaling pathway.
Limitations As a first point, with regards to the human
studies, one should keep in mind that we used the
Cockcroft–Gault formula to estimate the glomerular filtra-
tion rate. Though a suboptimal indicator, this formula is of
practical use because it provides a quantitative estimate of
the milliliters per minute loss of renal function in relation to
the variables considered. Another note of caution concerns
serum creatinine assay. Although creatinine had not been
assayed by a unique unit, we respected center consistency,
since each patient referred to his/her referring center that
was using the same intracenter standards. A number of
questions remain, however, unanswered. We have attemp-
ted to ascertain an association between a variety of genetic
manipulations of adducin and the glomerular phenotypes.
These include precise gene manipulations, like the knock-
out in mice, the introgression of DNA segments containing
the adducin loci from one inbreed rat strain to another and
genetic association studies in humans. Certainly, the
introgression of a DNA segment, harboring other genes
besides adducin [21], cannot exclude their influence on our
findings. However, this weakness is tempered by the
interaction between α- and β-adducin DNA segments. In
fact, the possibility that the other genes, mapping in close
vicinity to the adducin locus in the DNA fragment, display
Source β std err β [95% Conf. Interval] F value p value
Proteinuria −2.24 0.329 −2.892 −1.595 43.36 <0.0001
Follow-up after biopsy (years) 0.27 0.098 0.083 0.471 7.94 0.0052
α-Adducin (460Trp allele dominant) −0.15 1.091 −2.301 1.994 4.27 0.0397
β-Adducin (1797T allele dominant) −4.66 1.490 −7.594 −1.728 8.28 0.0043
Adducin interaction 4.45 1.863 0.787 8.117 4.93 0.0092
Table 5 ANOVA for statistical
model used to test effects of
interactions among ADD1
(α-adducin) and ADD2
(β-adducin) genotypes
Dependent variable: eGFR loss
(ml/min year)
J Mol Med (2010) 88:203–217 215such an interaction on the phenotypes we have measured is
unlikely in view of the biochemical requirement that α- and
β-adducin function as heterodimers [6] and that both
subunits are present in podocytes.
As in all the other studies aimed at establishing a
putative relationship between a given gene variation and
complex phenotypes, like progression of renal failure or
proteinuria, when we change the context, we increase the
number of confounding factors (such as variations in the
genetic and environmental backgrounds) that may differ-
ently modulate the effect of the gene variants of interest.
Therefore, we may anticipate some differences in the
phenotype effect. Moreover, in our case, adducin mutations
occur at different positions in rats and humans. In spite of
the very high identity between the adducin of the two
species (92%) and the many protein function similarities
between rat and human mutant variants [10], the difference
in the mutation site may produce protein function variations
that may differ across species.
Conclusions Genetic studies involve two major steps: (1) to
demonstrate that a given gene is involved in the regulation
of a phenotype and leads to disease (in our case, adducin
and glomerular permeability) and (2) to define the
mechanistic steps linking these gene variations to the
clinical phenotypes. While we believe we have provided
solid data to support the first step, the second one will
require further investigation to explore the mechanism
underlying the reduction of podocyte proteins that, in turn,
affects the glomerular permeability to proteins.
The wide range of contexts explored here strengthens the
conclusion that α-a n dβ-adducins are involved in
glomerular disease. We may speculate that the magnitude
of the adducin polymorphism impact on glomerular disease
of the individual patient may be modest, or more severe,
according to the individual genetic–environmental back-
ground. Certainly, adducin genetic variants seem to exert a
modifier rather than a triggering role within the heteroge-
neous network of the other podocyte gene polymorphisms.
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